A single chain immunotoxin, targeting the melanomaassociated chondroitin sulfate proteoglycan, is a potent inducer of apoptosis in cultured human melanoma cells
Introduction
Malignant melanoma represents the most common form of fatal skin cancer and accounts for 1-3% of all neoplasias. Its incidence has grown worldwide over the past few decades, especially among the Caucasian population due to intense sun exposure [1] . The 5-year survival rate drops from 95% for patients with a maximum tumor thickness of 1 mm lacking metastases (pathologic stage I) to below 10% for patients with visceral metastasis (pathologic stage IV) [2] . If distant metastases are present, disease progression is much faster, and life expectancy is commonly 6-9 months only [3] . Metastatic melanoma is largely resistant to known treatment modalities. In particular, the application of chemotherapeutics is not effective, owing to the resistance of melanoma cells to systemic treatment with anticancer agents [4] . Therefore, novel therapeutic options are needed, and immunotherapeutic approaches, targeting melanoma-associated antigens with restricted distribution in normal tissues, offer promising possibilities.
The melanoma-associated chondroitin sulfate proteoglycan (MCSP), also known as high molecular weightmelanoma associated antigen, is highly expressed on over 85% of human melanoma tissues, with a limited degree of intralesional and interlesional heterogeneity [5] . MCSP is also expressed in malignant lesions of nonmelanocytic origin, such as basal cell carcinoma, glioma, neuroblastoma and sarcoma [5] . Furthermore, MCSP is expressed on a subtype of leukemic blasts derived from patients with acute myeloid and acute lymphoblastic leukemia and its expression correlates with poor prognosis and balanced translocations into the mixed-lineage leukemia gene [6] . Interestingly, MCSP expression remains unaffected by chemotherapeutic treatment [7] . Because of its high expression on tumor cells and its restricted distribution in normal tissues, this antigen has been used as a target for antibody-based immunotherapy in patients with melanoma. Furthermore, toxins and chemotherapeutic agents chemically conjugated to MCSP-specific monoclonal antibodies (mAb) have been shown to control tumor growth both in vitro, and in animal model systems [8] [9] [10] [11] . An antigen-independent cytotoxicity of these conjugates may be caused at least in part by the limited stability of the link between the antibody and the toxin, and in part by the binding of the immunotoxin to antigen-negative, Fc-receptor-positive, nonmalignant target cells.
To overcome the limitations associated with the use of toxins chemically linked to mAb, in this study we have linked a toxic component to a single chain fragment variable (scFv) of the MCSP-specific mAb 9.2.27, to eliminate Fc-receptor-mediated uptake by nonmalignant cells. Moreover, in our design, we have used recombinant DNA technology to link the toxin to the antibody fragment to increase the stability of the bond and to reduce nonspecific uptake of the toxin resulting from a premature breaking of the bond in the extracellular space. Furthermore, we have selected the truncated version of exotoxin A (ETA 0 ) from Pseudomonas aeroginosa, which lacks domain Ia and consists only of domains Ib, II, and III [12] . Finally, in our molecule the endogenous C-terminal REDLK-peptide was replaced by the KDELpeptide, which has been shown to enhance cytotoxic activity by improving intracellular retrograde transport [13] .
Several groups have reported on scFv-ETA 0 -fusion immunotoxins of similar format targeting to CD22, CD25, CD7, CD64, CD33, CD19 and further antigens for the treatment of hematological malignancies [14] [15] [16] [17] [18] [19] . Other groups reported on such immunotoxins specific to the Lewis Y antigen, IL-13, the EGF-receptor, ErbB2/ HER2, EpCAM, and MUC1 for the treatment of solid tumors [20] [21] [22] [23] [24] [25] . These scFv-ETA 0 immunotoxins have not yet been approved for routine clinical use, but in preclinical and early-stage clinical studies they have demonstrated encouraging results. Especially for solid tumors, an immune response against the bacterial toxin is found to be the major limiting factor of ETA 0 -derived immunotoxins. A decrease in the production of ETA 0neutralizing antibodies was, however, achieved by pointmutations of the B-cell epitopes, which did not lead to a reduced cytotoxic activity [26] .
Taken together, scFv-ETA 0 immunotoxins have been found to be useful in early-phase clinical trials for the elimination of malignant cells from a variety of hematologic malignancies [14, 27] , but only a limited experience exists in the treatment of cells derived from solid tumors [20] . Therefore, we investigated in preclinical cellculture studies whether this format may also offer favorable properties for the treatment of human melanoma.
Materials and methods

Bacterial strains
Escherichia coli XL1-Blue and BL21 (DE3) were purchased from Stratagene, Amsterdam, The Netherlands and from Novagen Inc., Madison, Wisconsin, USA, respectively.
Culture of eukaryotic cells
The human melanoma cell line A2058 [28] was cultured in Dulbecco's modified Eagle's medium-Glutamax-I (Invitrogen, Karlsruhe, Germany), containing 10% fetal calf serum (FCS) (Invitrogen), 100 units/ml of penicillin, and 100 mg/ml of streptomycin (Invitrogen). The human melanoma cell line A375M and M14 [29] , the lymphoblastoid cell line CEM (Deutsche Sammlung von Mikroorganismen und Zellkulturen, DSMZ, German Collection of Microorganisms and Cell Lines, Braunschweig, Germany), and the hybridomas 9.2.27 [30] and 14G2a (both provided by Dr Ralph A. Reisfeld, Scripps Research Institute, La Jolla, California, USA) were maintained in Roswell Park Memorial Institute (RPMI) 1640-Glutamax-I medium (Invitrogen), containing 10% FCS, 100 units/ml of penicillin, and 100 mg/ml of streptomycin. The stably transfected M14-MCSP cell line [5] was cultured in RPMI 1640-Glutamax-I medium, containing 10% FCS, 100 units/ml of penicillin, 100 mg/ml of streptomycin, and 400 mg/ml Geneticin (Invitrogen).
Patient-derived melanoma cells
Primary human melanoma cells were obtained by surgical excision of solid metastatic tissues, which were mechanically disrupted to small pieces, using a Cell strainer 40 mm nylon membrane (Becton Dickinson, Heidelberg, Germany), and cultured in RPMI 1640-Glutamax-I medium, containing 20% FCS, 100 units/ml of penicillin, 100 mg/ml of streptomycin and 40 mg/ml Gentamycin (Sigma, Taufkirchen, Germany).
Construction and expression of the fusion protein MCSP-ETA
The MCSP-directed scFv was subcloned from the hybridoma 9.2.27 as previously described [16] . The sequence coding for the MCSP-specific scFv was inserted as an SfiI-cassette into the vector pASK6-linker, containing the coding sequences for the N-terminal STREP-tag and hexa-histidine-tag, and the 20 amino acid linker (G 4 S) 4 , which will connect the scFv to the truncated ETA 0 . The resulting vector, pASK6-MCSP-linker, was digested with NotI and XbaI, and the fragment containing the two tags, the MCSP scFv, and the linker was cloned into the expression vector pet27b( + ), upstream of the coding sequence for a truncated ETA 0 -REDLK variant [16] . The vector pet27b-STREP-His-MCSP-ETA 0 -REDLK was digested with XhoI and XmaI, for the exchange of the coding sequence for the C-terminal ETA 0 -KDEL [18] by digestion with XhoI and XmaI. Ligation created the expression vector pet27b-STREP-His-MCSP-ETA 0 -KDEL.
The scFv-ETA 0 -fusion proteins MCSP-ETA 0 , CD7-ETA 0 [16] , and CD33-ETA 0 [18] were expressed under osmotic stress conditions [31] . Cultures were harvested 20 h after induction. The bacterial pellet from 1 l of culture was resuspended in 200 ml of periplasmatic extraction buffer (100 mmol/l Tris, pH 8; 500 mmol/l sucrose; 1 mmol/l ethylenediaminetetraacetic acid) for 4 h at 41C. The scFv-ETA 0 -fusion proteins were enriched by affinity chromatography using streptactin agarose beads (IBA, Goettingen, Germany) according to the manufacturer's instructions.
Flow cytometric analysis
Adherent cells were harvested by incubation with 5 mmol/l ethylenediaminetetraacetic acid in phosphatebuffered saline (PBS) for 15 min at 41C. Following washings with phosphate-buffered bovine albumin (PBA) buffer, containing PBS, 0.1% bovine serum albumin, and 7 mmol/l sodium azide, 3 Â10 5 cells were incubated on ice for 60 min with 25 ml of an immunotoxin solution at the concentration of 5 mg/ml. The unrelated immunotoxins CD7-ETA 0 and CD33-ETA 0 served as controls for background staining of MCSP-ETA 0 and CD7-ETA 0 , respectively. Cells were washed in PBA and incubated on ice for 60 min with 25 ml of murine penta-His antibody (Qiagen, Hilden, Germany). Afterward, the cells were washed in PBA, and 25 ml of phycoerythrinconjugated goat-antimouse-IgG antibody (DAKO Diagnostica, Hamburg, Germany) was added, and incubation was continued for an additional 60 min on ice. After a final wash, cells were analyzed using a FACSCalibur instrument with CellQuest software (Becton Dickinson, Mountain View, California, USA).
To test primary melanoma cells for MCSP expression, adherent cells were harvested using the TrypLE Express harvesting reagent (Invitrogen). Following washing with PBA, 3 Â 10 5 cells were incubated on ice for 60 min with 25 ml of a murine mAb 9.2.27 solution at the concentration of 5 mg/ml. An unrelated murine IgG2a isotype (DAKO Diagnostica) served as the control for background staining. Cells were then washed with PBA and stained with phycoerythrin-conjugated antimouse-IgG as described above.
For each sample, 10 4 events were collected, and analysis of whole cells was performed using appropriate scatter gates to exclude cellular debris and aggregates. QIFIKIT (DAKO Diagnostica) was used for quantitative determination of MCSP expression on A2058 and A375M cells, according to the manufacturer's instructions. Equilibrium constants were determined using a flow cytometric assay as described before [32] .
Cell viability assay
Cell viability was measured using the CellTiter 96 AQ nonradioactive cell proliferation assay (MTS; Promega, Madison, Wisconsin, USA). A2058 cells were plated on 96-well plates at a density of 2000 cells /well in 80 ml of medium. After incubation at 371C for 14 h in a humidified 5% CO 2 atmosphere, the immunotoxin was added at the indicated concentrations to a final volume of 100 ml. After 72 h, 20 ml MTS/PMS solution was added according to the manufacturer's protocol and cells were incubated for 4 h at 371C. The absorbance at 490 nm was measured with a SPECTRA Rainbow Thermo microplate reader (Tecan, Salzburg, Austria). Five independent experiments were performed in triplicate.
Measurement of cytotoxic activity of immunotoxins and cyclosporin A
For dose-response experiments, 3 Â 10 4 cells/ml were seeded in 24-well plates in a final volume of 500 ml, and immunotoxin was added at varying concentrations between 0.01 and 2.5 mg/ml. Every sample measured represented one well, containing cells in the supernatant and adherent cells, which were removed by the TrypLE Express reagent. Cell death was measured by staining nuclei with a hypotonic solution of propidium iodide (PI) according to standard procedures. The extent of cell death was determined by measuring the fraction of nuclei with subdiploid DNA content. For each sample, 10 4 events were collected and analyzed for subdiploid nuclear DNA content.
To determine whether cell death occurred via apoptosis, cells were seeded at 3 Â 10 4 /ml in 24-well plates in a final volume of 500 ml, and immunotoxin was added at a concentration of 1 mg/ml. After incubation, whole cells were stained with FITC-conjugated Annexin V [33] (BD Pharmingen, San Diego, California, USA), and PI in PBS according to the manufacturers' instructions. For blocking experiments, the parental mAb 9.2.27, and the nonrelated, isotype-matched mAb 14G2a (targeting the ganglioside GD2), respectively, were added in 10-fold molar excess to the culture, 1 h before addition of the immunotoxin.
Cyclosporin A (CsA) (Sigma) was dissolved in EtOH at a concentration of 50 mg/ml, and used immediately or stored at -201C. For CsA experiments, cells were seeded at 3 Â 10 4 /ml in 24-well plates in a final volume of 500 ml, and CsA was added at the indicated concentrations, immunotoxin at 0.1 mg/ml, and mAb 9.2.27 at 0.22 mg/ml. Following a 72 h incubation at 371C, cell death was quantified by staining nuclei with a hypotonic PI-solution as described above. Synergistic cytotoxic effects induced by the combined treatment of cells with MCSP-ETA 0 and CsA were determined by evaluating the cooperativity index (c i ), defined here as the quotient of the sum of the percentages of cell death obtained with single agent Reducing and nonreducing sodium dodecyl sulfatepolyacrylamide gel electrophoresis was performed by standard procedures. Gels were stained with Coomassie brilliant blue R250 (Sigma). Western blots were performed with secondary antibodies coupled to horseradish peroxidase (Dianova, Hamburg, Germany). Enhanced chemiluminescence reagents (Amersham Pharmacia, Freiburg, Germany) were used for detection. ScFv-ETA 0 -fusion proteins were detected with a murine antipenta-his antibody (Qiagen), or with a polyclonal rabbit anti-Pseudomonas ETA serum (Sigma). Full-length poly ADP-ribose polymerase (PARP) and its specific cleavage product were detected using a mouse antihuman-PARP antibody (BD Pharmingen). The immunotoxin was analyzed by size-exclusion chromatography using a Superose 12 10/300 GL column (GE Healthcare, München, Germany) eluted at 41C with a PBS buffer containing 10% glycerol and 0.02% sodium azide. Aldolase (158 kDa), bovine serum albumin (67 kDa), ovalbumin (43 kDa), and RNAse A (15 kDa) served as standard proteins.
Statistical analysis
Statistical analysis was performed using Microsoft EXCEL software. P values were obtained using t-tests with a confidence interval of 95% for evaluation of the statistical significance compared with the control.
Results
Construction, expression, and purification of the recombinant immunotoxin
The MCSP-directed scFv was subcloned from the hybridoma 9.2.27 by phage display as described [16] , and fused to the coding sequence for truncated Pseudomonas ETA. To improve retrograde transport through the trans-Golgi network, the REDLK-motif was replaced by the endoplasmic reticulum retention motif KDEL of eukaryotic cells. Variable light (V L ) and heavy (V H ) chain domains were connected in this order by a 20 amino acid flexible linker (G 4 S) 4 . The same linker was used to connect the scFv moiety to the ETA 0 polypeptide. For purification and specific detection, an Nterminal STREP-tag and a hexa-histidine-tag were added (Fig. 1a ). The resulting construct was cloned into the bacterial expression vector pet27b, and expressed in E. coli BL21 (DE3) under osmotic stress conditions. The recombinant immunotoxin was highly enriched after a single purification cycle under native conditions using streptactin beads (Fig. 1b) . The yield was approximately 20-30 mg/l of bacterial culture. In Western-transfer experiments, the immunotoxin was bound by antibodies specific to the ETA 0 -moiety ( Fig. 1c ). Sodium dodecyl sulfate-polyacrylamide gel electrophoresis under nonreducing conditions and western-transfer-experiments detecting the hexa-histidine-tag showed an absence of potential protein aggregates covalently linked by a false formation of disulfide bonds (Fig. 1d ). Size exclusion chromatography of the purified immunotoxin exhibited one single peak with an apparent molecular mass of approximately 70 kDa (12.38 ml elution volume) suggesting that the protein is predominantly present as a monomer (Fig. 1e ).
Antigen-specific binding of MCSP-ETA
To determine whether the described scFv-ETA 0 -fusion protein is capable of specific binding to MCSP, the immunotoxin was incubated with M14-MCSP human melanoma cells, a cell line stably transfected with MCSP c-DNA, and as a control with the parental MCSPnegative cell line M14. MCSP-ETA 0 showed effective binding to M14-MCSP cells ( Fig. 2a ), whereas no binding was detected to the parental MCSP-negative M14 cells ( Fig. 2b) . Additionally, MCSP-ETA 0 binds to MCSPpositive A2058 ( Fig. 2c ) and A375M ( Fig. 2d ) melanoma cells. For comparison, the similarly constructed CD7specific immunotoxin [16] was tested for binding to CD7-positive CEM-cells. The CD7-specific immunotoxin did bind to these cells ( Fig. 2e ), but did not bind to MCSP-positive, CD7-negative A2058 cells ( Fig. 2f ). Antigen-specificity of the binding by MCSP-ETA 0 to intact cells was further demonstrated by blocking experiments with 10-fold molar excess of the mAb 9.2.27 in cytotoxicity experiments (see below). In summary, the data show that the MCSP-ETA 0 did bind to MCSP in an antigen-specific manner. The measured equilibrium constants of the 9.2.27 parental antibody, the subcloned scFv, and the fusion protein MCSP-ETA 0 were 5 ± 0.5, 43 ± 8, and 134 ± 3 nmol/l, respectively (data not shown).
Dose-dependent and antigen-specific cytotoxic activity of MCSP-ETA
To determine cytotoxic activity of MCSP-ETA 0 , the agent was incubated with MCSP-positive cultured human melanoma cells A2058 and A375M. These cells expressed 168 ± 21 Â10 3 and 195 ± 21 Â10 3 antigenic sites, respectively, as determined by a quantitative analysis of MCSPantigen molecules per cell (data not shown). As control, MCSP-negative human melanoma cells, M14, were used. Cell death was quantified by PI staining and flow cytometry 72 h after treatment. MCSP-ETA 0 specifically mediated cell death of the MCSP-positive A2058 and A375M cells in a dose-dependent manner, but had no detectable effects on MCSP-negative human melanoma cells M14 (Fig. 3a) . The determined concentration of the agent (applied as a single dose) needed to reach the halfmaximum cytotoxic effect (EC50) following 72 h of incubation at 371C was approximately 60 ng/ml (0.9 nmol/l) for A2058 cells and 80 ng/ml (1.1 nmol/l) for A375M cells. Statistically significant cell death of MCSP-positive cells (P < 0.05), compared with untreated cells, was obtained at MCSP-ETA 0 concentrations of Z 10 ng/ml (0.14 nmol/l) ( Fig. 3a) . In an additional experiment, 1 mg/ml of immunotoxin was given at time zero, and additional doses of 1 mg/ml were added after 24 and 48 h. This did not lead to an increased maximum cytotoxicity for both cell lines after 72 h of incubation (data not shown). A second approach to measure the dose-dependent activity of MCSP-ETA 0 against melanoma cells was the use of the MTS cell-viability assay (Fig. 3b ). MCSP-ETA 0 reduced cell viability of A2058 cells with a half-maximum inhibitory concentration (IC50) value of approximately 12.7 ng/ml (187 pmol/l).
The cytotoxic effect was antigen-specific as preincubation of the A2058 (Fig. 4a ) and A375M (Fig. 4a ) cells with the MCSP-specific parental mAb 9.2.27 in a 10-fold molar excess inhibited cytotoxicity by the immunotoxin. The inhibition was specific, as preincubation of the cells with the GD2-specific, isotype-matched mAb 14G2a at a similar molar excess failed to block the cytotoxic effect of the immunotoxin. It is noteworthy that the isotypematched mAb used as a single agent had no detectable cytotoxic effect on melanoma cells. As a further control, the CD7-ETA 0 immunotoxin of a similar format displayed no antigen-independent cytotoxic potential against CD7-negative melanoma cells (Fig. 4 ). In conclusion, MCSP-ETA 0 acted in a highly antigen-specific and dosedependent manner and showed cytotoxic potential against MCSP-positive human melanoma cells in a low nanomolar concentration range.
Antigen-specific induction of apoptosis by MCSP-ETA
To evaluate whether cell death was attributable to apoptosis, cells were analyzed by Annexin V and PI double staining in flow cytometric studies. MCSP-ETA 0treated, MCSP-positive A2058 (Fig. 5a ) and A375M (Fig. 5b ) cells displayed Annexin V-positive and PInegative staining. This subpopulation reflects cells in an early apoptotic stage. Ninety-six hours after treatment, 40% of the A2058 cells were in the early apoptotic stage and an additional 20% were dead (Fig. 5a ). Seventy-two hours after treatment, 32% of the A375M cells were in the early apoptotic stage and an additional 38% were dead (Fig. 5b ). This cytotoxic effect was blocked by preincubation of target cells with the parental mAb 9.2.27 in a 10-fold molar excess ( Fig. 5a and b) . The apoptotic nature of cell death was further demonstrated by the cleavage of PARP. MCSP-ETA 0 promoted the cleavage of intact PARP (116 kDa) to its characteristic 85 kDa proteolytic fragment in A2058 ( Fig. 5c ) and A375M ( Fig. 5c ) cells 48 h after treatment. Thus, two independent methods have shown that MCSP-ETA 0 induced apoptosis in long-term cultured human melanoma cells in an antigen-specific manner.
MCSP-ETA induces cell death of cultured primary melanoma cells
Owing to the fact that long-term cultured cancer cells only inaccurately represent the features of the parental tumor cells, the immunotoxin was tested on cultured, primary melanoma cells. Therefore, melanoma cells from metastatic lesions, surgically removed from 10 patients with advanced disease (stage IIIC and IV), were treated with a single dose of 1 mg/ml MCSP-ETA 0 or 1 mg/ml of a similarly constructed, unrelated control toxin. At indicated time-points, cell death was determined by PI staining of nuclei and flow cytometric analysis (Table 1 and Fig. 6 ). Specific cell death (net above spontaneous cell death of untreated cells) in cells from patients 3, 4, 7 and 8 occurred in a time-dependent manner and ranged from 44 to 69% following a 96 h incubation at 371C, with a background varying between 17 and 23% (Fig. 6 ). In the 10 samples, the percentage of MCSP-positive cells, representing the melanoma cells, ranged from 14 to 99%, as determined by the flow-cytometric analysis of cells stained with mAb 9.2.27 before incubation with the immunotoxin. Table 1 summarizes the data obtained with the cell samples from the 10 melanoma patients. Thus, MCSP-ETA 0 displayed a cytotoxic effect also against primary melanoma cells.
MCSP-ETA cooperates with the antitumor effect of cyclosporin A in a synergistic manner
Beside its immunosuppressive properties, CsA has been shown to induce apoptosis in human melanoma cells [34] . To examine synergistic effects of CsA and MCSP-ETA 0 , the human melanoma cell line A2058 (Fig. 7a ) was incubated for 72 h at 371C with varying concentrations of CsA as a single agent, or with CsA in combination with a constant concentration of MCSP-ETA 0 , and cell death was evaluated by PI staining of nuclei and flow cytometry. When used as a single agent, CsA induced cell death in A2058 cells at concentrations ranging from 10 to 25 mg/ml (Fig. 7a ). When used in combination with 100 ng/ml MCSP-ETA 0 , cell death was markedly enhanced. The c i for 1, 5 and 10 mg/ml CsA and 100 ng/ml MCSP-ETA 0 ranged from 0.56 to 0.66, indicating a strong synergistic effect of these two agents (Fig. 7a) . To assess the role of intracellular signaling induced by antibody-binding to MCSP in the synergistic effect of CsA and MCSP-ETA 0 , A2058 cells were incubated with varying concentrations of CsA in combination with the unmodified parental mAb 9.2.27 used in a concentration, equimolar to MCSP-ETA 0 (Fig. 7a) . No increase in cytotoxicity was detected, excluding any major role of the binding to MCSP in the synergistic effect of the combination of CsA with MCSP-ETA 0 .
A similar synergistic cytotoxicity was found when melanoma cells from patient 4 were used as targets (Fig. 7b ). In the latter case, cells were incubated for 48 h at 371C with CsA as a single agent at 5 and 10 mg/ml, or with CsA in combination with 1 mg/ml MCSP-ETA 0 . Cytotoxicity was not detected when cells were incubated with CsA alone, but was increased when cells were incubated with CsA in combination with MCSP-ETA 0 . This effect was also synergistic, as indicated by a c i of 0.65 (Fig. 7b ).
In summary, these results show that MCSP-ETA 0 and CsA synergize in their cytotoxic effects for both long-term, established melanoma cell lines and primary melanoma cells.
Discussion
The purpose of this study was to determine whether the format of a fusion-protein consisting of a tumor-antigenspecific single chain antibody fragment and a truncated Pseudomonas ETA 0 toxin exhibits cytotoxic potential against melanoma-derived cells. The results we obtained were (a) the MCSP-ETA 0 fusion protein was capable of eliminating both established melanoma-derived cell lines and cultured primary melanoma cells from melanoma patients, (b) the cytotoxic effect was highly antigenspecific, (c) cell death occurred via apoptosis, and (d) the agent cooperated with the cytotoxic potential of CsA in a synergistic manner.
The agent eliminated the two MCSP-positive human melanoma cell lines A2058 and A375M with similar efficacy. For both lines, the EC50 dose was approximately 1 nmol/l, which is a low effective concentration comparable with other immunotoxins of a similar format [14, 17] . An immunotoxin, consisting of an intact MCSP-antibody, 1  F  32  IV  M1c  94  84  2  16  14  21  2  F  77  IV  M1b  98  320  6  8  14  25  3  F  40  IV  M1c  64  182  15  26  26  45  4  F  71  III C  -95  329  12  27  39  44  5  M  3 0  I V  M 1 c  9 8  4 7 5  3  4  3  8  6  M  30  IV  M1a  94  425  5  4  7  -7  F  6 7  I I I C  -9 9  5 0 4  1 2  1 9  3 5  5 5  8  M  40  IV  M1c  99  627  6  39  57  69  9  F  61  IV  M1c  14  11  2  11  14  17  10  F  59  IV  M1c  97  507  3  4 chemically linked to wild-type ETA, has already been published [11] . This agent eliminated human glioblastoma-derived cells in an animal model, and, therefore, the MCSP-antigen must be sufficiently well internalized after binding of a bivalent antibody to present a favorable target for immunotoxins. Nevertheless, it was not known so far that monovalent binding to MCSP is sufficient to induce receptor-mediated internalization. Furthermore, it had to be determined whether a similar immunoconjugate, or a format derived from it, would also be effective for melanoma cells.
It might be expected that our molecule displays less side effects in a potential clinical application, compared with the published MCSP-directed immunotoxin containing the whole mAb chemically linked to wild-type ETA [11] . The published compound would probably be resorbed by human Fc-receptors on nonmalignant, antigen-negative cells, owing to the presence of the murine IgG2a Fc-part, thus possibly causing severe side effects. Moreover, the existence of wild-type ETA, including its natural binding domain I, would allow an extracellular cleaved toxin to enter MCSP-negative, nonmalignant cells. Furthermore, the tissue penetration, which is an important property of immunotoxins targeting solid tumors, is expected to be improved owing to the reduced size of our scFv-ETA 0 immunotoxin (approximately 66 kDa), compared with the published immunoconjugate (approximately 216 kDa).
We found a gradual loss of avidity after subcloning the scFv and by fusing the truncated ETA 0 to the variable heavy chain of the antibody-fragment. The first minus might be due to the reduced number of binding heads of one molecule. The loss of avidity of the MCSP scFv is in a comparable range with another reported case in the literature [35] . The fused ETA 0 component might impair the pairing of the heavy and the light chain, which then leads to an additional reduced affinity. Further approaches such as affinity maturation of the scFv might help in improving this important property in the future with regard to potential clinical use.
The survey of metastatic tissue samples of 10 melanoma patients with advanced disease (Table 1 ) demonstrated that cells from some patients were more susceptible to the agent than others, such as cells from patients 5 and 6. The lack of sensitivity of cells from these patients cannot be attributed to the low percentage of MCSP-positive cells in these cultures, because in both cases, more than 90% of the cells were highly antigen-positive. We suspect that the different response rates reflect heterogeneity in the pattern of genetic alterations that is specific to every tumor and even for subclonal lines within the tumor of every patient. Although these cells probably are, as is the case for most solid tumors, clonal descendants of one original, malignantly transformed cell, they probably represent different subclonal lineages present in the tumor tissue. Each of these subclones, in addition to carrying the initial set of genetic alterations that led to malignant outgrowth, would carry a subclone-specific pattern of additional mutations, which may influence their relative susceptibility for our agent. In a recent cancer-genomics study of primary breast and colon carcinoma, a surprisingly high number of mutations were reported, on the order of 100 mutations per cell, with several dozen mutations per cell in known oncogenes and tumor-suppressor genes [36] . If a similar pattern was applicable for melanoma cells, then it would not be surprising to find differences in the susceptibility to the novel agent for different subclonal lines within different patients, or even the tumor tissue of the same patient. We do not, however, consider it a discouraging result that 6 of 10 patient samples showed a response to our agent, considering the the fact that all the patients had already received standard chemotherapeutic treatment before surgical excision of the metastatic tumor cells used in these studies. Presumably some cells already gained further resistance to apoptosis-inducing agents owing to the prior treatment of the patients with chemotherapeutics. Taken together, the positive result of our study was that tumor cells from six of 10 patients showed a clear response to the agent, plus another two of 10 showed marginal responses above background of spontaneous cell death. Under these conditions, and given the limited success of chemotherapeutic agents for the treatment of melanoma, the obtained results have to be considered positive.
The new agent would probably present some shortcomings, when considered as an anticancer drug for the treatment of solid tumors. One source of concern might be the use of the ETA 0 moiety as the toxic component. Upon multiple administration of immunotoxins containing bacterial toxins, neutralizing antibodies have often been observed in a fraction of the patients, precluding further use of the agent [37] . Despite this known disadvantage, ETA 0 -based immunotoxins are currently under consideration for further development for the treatment of selected types of solid tumors, including breast cancer and head-and-neck cancer [23, 24] . Such agents may, therefore, also be useful for the treatment of melanoma. To reduce the immunogenicity of the bacterial toxin, several investigators have considered a combination-treatment of the patients with immunosuppressive agents, such as CsA. Interestingly, CsA not only functions as an immunosuppressive agent, but also has an intense ability to induce apoptosis in certain types of tumor cells, including gliomas, melanomas, and leukemias [34, 38, 39] . CsA acts as a modulator of the mitochondrial permeability transition pore to induce apoptosis [40] , and a similar mode of action has also been reported for Pseudomonas ETA [41] . Moreover, CsA synergizes with other antitumor agents, that act on mitochondria, such as resveratrol, at least for leukemic cells [42] . Published reports suggest that CsA binds to cyclophilins and thereby inhibits their peptidyl-propyl-cis-trans-isomeraselike activity [43] . Peptidyl-propyl-cis-trans-isomerase-like enzymes act as molecular chaperones to support protein folding, intracellular transport, and the maintenance of stability of multiprotein complexes [44] . Apart from its interaction with cyclophilin D inside the mitochondrial membrane [45] , and the ensuing direct effect on apoptosis, CsA may therefore also produce additional indirect proapoptotic effects, which may synergize with ETA. Regarding both the agents influence on protein synthesis, it would be easy to conceive synergistic proapoptotic effects for the combination of ETA and
CsA. Therefore, we were gratified to find that our MCSP-ETA 0 molecule showed synergistic effects with CsA in the elimination of cultured melanoma cells. An enhancement of cytotoxic activity has also been reported for CsA and an anti-Tac-ETA 0 immunotoxin in the treatment of acute T-cell leukemias [46] . This property makes our agent particularly attractive for further development, because it would simultaneously suppress the neutralizing response against the toxin and achieve a synergistic antitumor effect. Current research in the field of ETA 0derived immunotoxins shows further promising results. The mutation of characterized B-cell epitopes inside the polypeptide chain of ETA 0 reduces the production of neutralizing antibodies without losing its cytotoxic potential [26] .
Interestingly, MCSP expression is often correlated with an immature character of the affected cell. This property has been reported for melanoma cells with stem cell-like properties [47] , and for leukemic blasts with chromosomal rearrangement of the mixed-lineage leukemia gene, which often have a stem cell-like phenotype [48, 49] . In addition, MCSP is expressed on epidermal and hair follicle progenitor cells [50] , which also have stem celllike properties, but not on the corresponding mature cells. Taken together, these observations indicate that MCSP may be expressed on cells with stem cell-like properties and possibly on melanoma tumor stem cells [47] . Therefore, MCSP is a particularly attractive target, because the elimination of tumor stem cells might be a high-ranking objective for every cancer therapy in the future.
In summary, the study presented here demonstrated that an immunotoxin consisting of an MCSP-specific scFv fused to a truncated Pseudomonas exotoxin A effectively eliminated both MCSP-positive melanoma cell lines and primary cells from melanoma patients with advanced disease in low nanomolar concentrations, and that the agent showed a striking degree of synergism with CsA. On the basis of available knowledge in the field, this format might be expected to offer significant benefits in the treatment of malignant melanoma, as a single agent or in a combination therapy, and therefore deserves further characterization in view of its advancement toward preclinical and clinical investigation. 
